Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (November 2017)
27 slides from Aurobindo Pharma's investor presentation, November 2017
Slide 1: Investor Presentation November 2017
INVESTOR PRESENTATION November 2017
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Company Overview
Company Overview Among the Top-3 listed pharmaceutical companies from India by sales(1) Overview- by the number 5th largest generic company by volume in the US; IMS TRx represents greater than 20% growth year over year(2) Broad portfolio of diversified dosage forms including Rx and OTC oral IN
Slide 4: The Journey So Far…
The Journey So Far… 2013 Commenced marketing specialty injectables in USA Building capabilities in Penem and Oncology 2006-08 Acquired UK based Milpharm 2014 Acquired formulations facility Acquired Western European in US commercial operations from Investment in building Actavis manufactu
Slide 5: Strong Operational Growth & Diversified Revenue Base
Strong Operational Growth & Diversified Revenue Base INR Cr FY13 CAGR FY17# Revenue from 5,855 27% 15,090 operations EBITDA 889 40% 3,434 EBITDA 15.2% 22.8% Margin (%) PAT** 294 67% 2,302 PAT Margin 5.0% 15.3% (%) ANDA Filed 269 429 Formulations Formulations Revenue : 57% : 79.8% Breakup API: 43% AP
Slide 6: Our Business Segments
Our Business Segments US EU Ranked 5th* Rx supplier as per Among top 15** Gx companies IMS total prescriptions dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics, speciality products UK, Portu
Slide 7: US Business Overview
US Business Overview AuroLife Pharma Aurobindo USA AuroMedics AuroHealth Natrol Manufacturing / Oral Rx Injectables Pharma OTC Dietary Supplements R&D Cumulative ANDA Filings and Approvals Gross Sales (INR Cr) 40% CAGR in FY13-FY17 Unit wise ANDA Filings as on 30-Sep-2017 Growth Drivers in the next
Slide 8: US: Expanding Portfolio Mix Towards Differentiated Products
US: Expanding Portfolio Mix Towards Differentiated Products Portfolio mix is complemented with the introduction of high-value products Addressable Market at US$ 91.2 Bn including ~US$ 63.2 Bn for Under Review and Tentatively approved ANDAs Future pipeline to include Oncology, Hormones, Depot injecti
Slide 9: Natrol
Natrol Amongst the top 20 branded Dietary Supplements companies in US Diverse Customer Base with long term relationships with key distribution and retail partners Strong customer partnerships across multiple distribution channels with growth potential within each channel R&D capabilities in
Slide 10: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium India’s Leading Gx company with strong footprint in Europe Gross Sales** Operations in 9 countries with full fledged sales force & support infrastructure 63% CAGR in FY13-FY17 Significant presence and posit
Slide 11: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Channels Gx BGx Hx TGx Germany, Spain Geographies All 9 countries 7 countries All 9 countries & Netherlands 769 (primarily 347 (predominantly 767 (including Gx # of Products 34 tab
Slide 12: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Gross Sales (INR Cr) Global Fund, USAID/PEPFAR and Country specific MOH tenders; 12% CAGR in FY13-FY17 currently caters to 2.2 million HIV+ patients Well integrated supply chain management services and logi
Slide 13: Growth Markets Business Overview
Growth Markets Business Overview Canada Ukraine GCC Countries Myanmar Mexico Tanzania Colombia Brazil South Africa Growth markets Gross Sales (INR Cr) Growth Drivers in the next 3-4 years 800 7 16% CAGR in FY13-FY17 8 6 Build branded generics presence 600 5 5 756 5 6 437 5 Enhance penetration in
Slide 14: The Base Business : API
The Base Business : API API business continue to focus on high value, specialty, Gross Sales (INR Cr) small/mid-size products with a limited competition 5% CAGR in FY13-FY17 Ensures quality & Reliability of supplies and ability to command cost efficiencies as well as economies of scale Focus o
Slide 15: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities 5 R&D centers in Hyderabad, India Focused on difficult to develop API, niche oral, sterile and specialty injectable Concentrating on wide range of Oncology, Hormonal products, Penems, Enzymes, Biocatalysts, vaccines and Peptides Developing diverse p
Slide 16: Consolidated Financial Performance
Consolidated Financial Performance Q2 Q2 % Q1 % Value INR Cr FY18 FY17 Chg FY18 Chg Formulations 3,663.3 3,003.8 22.0 3,051.0 20.1 API 771.8 768.8 0.4 625.0 23.5 Formulations % of sales 82.6% 79.6% 83.0% Revenue from Operations 4,435.9 3,775.5 17.5 3,678.7 20.6 (including excise duty) Gross Profit 2
Slide 17: Financial Performance
Financial Performance Revenue from operations (INR Cr) EBITDA & PAT Margin (%) EPS (INR/Share) Gross Block & Fixed Asset Turnover Average ROE & ROCE % Net Debt/Eq & Net Debt/EBITDA Gross Block is calculated as Tangible Assets + Intangible Assets-Goodwill 16 * As per Ind AS, **includes sales from lim
Slide 18: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-15 Mar-16 Mar-17 Sep-17 Closing Rate1 US$ = 62.50 66.255 64.85 65.285 INR Fx Loan restated in 4,312.3 4,956.7 3,121.5 4,930.6 690 748 481 755 INR Rupee Loan 37.3 46.9 244.8 70.1 Sales Tax Deferment 54.9 41.9 0.0 0.0 Gross Debt 4,404.5 5,045.6 3,366
Slide 19: New Business and Technology Initiatives to Support Growth
New Business and Technology Initiatives to Support Growth Peptides Manufacturing peptides from short to long chain molecules supporting mg to kg scale Highly Experienced team of scientists; developed technologies for over 10 products Four DMFs filed & 4-5 more products will be filed in FY18
Slide 20: Way Forward
Way Forward Market share gain for existing products and introduction of new products including limited Orals competition products (currently 128* ANDAs under review/tentatively approved) 41* ANDA filings under review/tentatively approved for injectables along with a pipeline of Injectable Oncology,
Slide 21: Annexure
Annexure 20
Slide 22: Gross Sales Break-Up
Gross Sales Break-Up FY16 FY17 FY18 INR Bn Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 USA 14.1 14.7 15.6 16.3 60.8 17.0 17.4 17.5 16.4 68.3 16.9 21.0 Europe 7.4 7.6 7.8 8.4 31.3 8.3 8.1 8.6 7.8 32.8 9.2 11.1 Growth Markets 1.6 1.6 1.6 1.6 6.5 1.9 1.8 1.9 2.0 7.6 1.9 2.4 ARV 3.0 2.8 3.1 3.3 12.1 3.0 2.8 3.4
Slide 23: 5 Year Financial Snapshot
5 Year Financial Snapshot Value INR Bn FY13 FY14 FY15 FY16* FY17* Net Operating Income 58.6 81.0 121.2 139.6 150.9 Gross margin % of operating income 48.9% 55.5% 54.6% 55.8% 57.4% EBITDA (before Fx and other income) % to 15.2% 26.4% 21.2% 22.8% 22.8% Operating income Depreciation / Amortization 2.5
Slide 24: Filing details as on 30th Sep 2017
Filing details as on 30th Sep 2017 As at As at As at As at As at As at Category Approvals Mar 13 Mar 14 Mar 15 Mar 16 Mar 17 Sep 17 Formulations 334 (FA: 294, US* 269 336 376 398 429 463 TA:40) 1,874 Europe** 1,341 1,542 1,756 2,224 2,521 2,735 Dossiers (199 products) 185 SA** 314 334 345 376 401 40
Slide 25: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / Orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics)&Oph
Slide 26: Shareholding Pattern
Shareholding Pattern As on As on As on Group 31 Mar 16 31 Mar 17 30 Sep 17 Non-Promoter Holding 48.1% Promoter Group 53.9% 51.9% 51.9% FII 27.4% 21.0% 18.8% MF / Insurance 7.2% 12.4% 15.2% Other Bodies Corporates 2.4% 3.6% 3.4% Retail Investors 9.1% 11.1% 10.7% Total 100% 100% 100% Equity Shares (in
Slide 27: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Krishna Kiran Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 5
Aurobindo Pharma — Investor Presentation (November 2017) on 6ix